Back to Home Page of CD3WD Project or Back to list of CD3WD Publications

CLOSE THIS BOOKFact sheet No 179: Lassa Fever - New draft: April 2000 (WHO, 2000, 3 p.)
VIEW THE DOCUMENT(introduction...)
VIEW THE DOCUMENTClinical illness
VIEW THE DOCUMENTDiagnosis
VIEW THE DOCUMENTEpidemiology
VIEW THE DOCUMENTOutbreaks

Diagnosis

· The clinical syndrome of Lassa fever is difficult to distinguish from severe malaria, septicaemia (infections of the bloodstream), yellow fever and other viral haemorrhagic fevers (e.g., Ebola). Inflammation of the throat with white tonsillar patches is an important distinguishing feature.

· Definitive diagnosis requires testing that is available only in highly specialized laboratories. Laboratory specimens may be biohazardous and must be handled with extreme care at the highest level biosafety containment.

Treatment Specific treatment with the anti-viral drug, ribavirin may be effective if given within the first six days of illness. Ribavirin should be given intravenously for ten days.

TO PREVIOUS SECTION OF BOOK TO NEXT SECTION OF BOOK